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Natural products represent valuable lead structures for drug discovery. However, for 
most bioactive compounds no cellular target is yet identified and many substances 
predicted from genome analysis are inaccessible due to their life-stage dependent 
biosynthesis, which is not reflected in common isolation procedures. In response to these 
issues an NMR based and target directed protease assay for inhibitor detection of the 
proteasome was developed. The methodology is suitable for one-shot identification of 
inhibitors in conglomerates and culture broths. The technique was applied for analysis 
of the different life-stages of the bacterium P. luminescens, which resulted in the 
isolation and characterization of cepafungin I (CepI), the strongest proteasome inhibitor 
described to date. Its biosynthesis is strictly regulated and solely induced by the specific 
environmental conditions determined by our methodology. The transferability of the 
developed technique to other drug targets may disclose an abundance of novel 
compounds applicable for drug development. 
The eukaryotic proteasome core particle (CP) is a 720 kDa multicatalytic protein degradation 
machinery and constitutes the main non-lysosomal protein degradation system in cells (1, 2). 
Its structure is composed of four stacked heptameric rings which contain the active subunits 
β1, β2 and β5 with an electrophilic Thr-1Oγ at their N-termini (3-5). They exhibit the 
proteolytic activities denominated caspase-like (CL), trypsin-like (TL) and chymotrypsin-like 
(ChTL) according to the chemical nature of their specificity pockets (6).  Being involved in 
many cellular processes such as cell proliferation and antigen presentation, the CP is a 
potential target for the treatment of diseases as diverse as cancer or autoimmunity (7). The 
blockbuster drug Velcade, a synthetic dipeptide boronic acid, was the first proteasome 
inhibitor approved for cancer therapy (8). However, because of its severe side effects (9) and 
the vast potential of proteasome inhibitors with regard to other diseases (7), there is a high 
demand for the development of novel agents. Lead structures for new drugs are often deduced 
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from natural compounds, as they are evolutionary optimized (10). A current and highly 
prominent example is Carfilzomib, a proteasome inhibitor in clinical phase III trials (11), 
which was derived from the natural product inhibitor epoxomicin (12, 13). Although other 
natural compounds have been elucidated in past decades (10), a persistent challenge for the 
identification of potent proteasome inhibitors still remains. However, in our days natural 
product research suffers generally from two major limitations. First, for most compounds 
described in literature, no cellular target has been identified so far. In general, this complicates 
the rational application of bioactive compounds. Second, the life-stage dependent metabolite 
pattern of many organisms is not reflected by commonly applied growth conditions, thus 
leading to a severely limited accessibility within the huge spectrum of natural substances.  
Results  
Development of an NMR based proteasome assay. Addressing both issues, we have 
developed a novel proteasome assay for screening of inhibitor secretion under various  growth 
conditions. It uses a peptide substrate of the CP, which was atom-selectively labeled for NMR 
spectroscopy and derived from the digestion pattern of the murine JAK1 tyrosine kinase, a 
well characterized natural substrate of the 20S proteasome (14). The peptide sequence is 
adapted towards specificity for the ChTL activity as inhibitors against the corresponding β5 
subunit exert high cytotoxicity and strongly influence adaptive immune response by MHCI 
presentation. By introducing a carbonyl 13C probe at the scissile bond, hydrolysis can be 
qualitatively and quantitatively evaluated by a peak shift in the 13C-NMR spectrum from 173 
to 177 ppm, corresponding to the amide educt and the carboxylic acid product, respectively 
(Fig. 1). Synthesis of the substrate was achieved by standard Boc-based solid phase peptide 
chemistry, whereas the peptide cleavage site was determined by LC-MS analysis of the 
digestion products in an in vitro assay. Confirming the specificity of the probe molecule 
towards the β5 subunit, the hydrolysis was prevented in the same assay after addition of the 
  
4 
 
synthetic boronic acid inhibitor MG262 (15), which exhibits inhibition merely of the ChTL 
activity. 
The assay displays the superiority of NMR techniques over common UV-Vis and 
fluorescence based methods by overcoming color quenching artifacts, which produce a 
plentitude of false positive or negative results in high-throughput arrays. In contrast, the 
developed approach yields unambiguous readout information and is applicable to extremely 
heterogeneous and colored conglomerates present, for example, in culture media. The 
technique is suitable for high-throughput analysis, as the recording time in a standard 500 
MHz NMR machine, equipped with an autosampler, is only about 15 minutes per assay. Thus, 
a typical sample number of 96 experiments can be processed within one day. With a volume 
of approximately 500 µl, the methodology allows to screen a large number of small cultures at 
different growth conditions in short periods. 
Application of the technique in a real-case scenario. For evaluation of the NMR assay by a 
positive control, we analyzed secretions of Pseudomonas syringae, which causes the brown 
spot disease in common bean plants and whose virulence is decisively determined by the 
proteasome inhibitor syringolin A (SylA), a member of the syrbactin family. The bacteria 
were grown in SRMAF medium, which contains the phenolic sugar arbutin present in plant 
leaves for induction of the pathogenic phase (16). The crude broth was then added to the assay 
mixture containing yeast CP. After an incubation period of only 10 minutes, 13C labeled 
peptide substrate was added. NMR analysis of the digestion showed complete suppression of 
product formation, thus demonstrating the presence of proteasome inhibiting substances. 
Despite the high chemical heterogeneity covering all types of biomolecules present in culture 
broth, the signal to noise ratio in the decisive spectral range from 173 to 177 ppm was 
unaffected by interference. Confirming the univocal results gained by our novel method, SylA 
was purified from the respective culture broth and analyzed by HPLC as described (16). 
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Identification of candidate organisms for analysis. Next, we aimed to identify other 
organisms producing inhibitors against the CP. SylA is produced in vivo by a non-ribosomal 
peptide synthethase, which is constituted by an array of enzymes responsible for attachment 
of amino acid building blocks and introduction of chemical modifications. SylD, a 460 kDa 
multidomain enzyme, represents the major part of this assembly line and was chosen for 
BLAST alignment (17, 18). The search yielded hits among various Photorhabdus and 
Burkholderia species, which can therefore be suggested to produce analogous natural 
products. This group also comprises Burkholderia pseudomallei, the causative agent of 
melioidosis (19). Intriguingly, the related but less human pathogenic bacterium Burkholderia 
mallei, carries an analogous gene cluster, which is inactivated by transposon-mediated 
rearrangement, hence suggesting a significant contribution to virulence of the respective 
proteasome inhibiting compound (17). From this group of organisms, we chose the insect 
parasite bacterium Photorhabdus luminescens, as this S1 pathogen can be handled easily. The 
organism secretes intensely red-colored compounds (20, 21) not suitable for analysis with 
common assay types, hence representing a perfect candidate for a proof of concept of our 
detection method.  
Induction of the pathogenic phase in P. luminescens. Photorhabdus was grown in SRMAF 
medium containing the phenolic sugar arbutin present in leaves, which induces secretion of 
the SylA virulence factor from the plant pathogen P. syringae (22). However, no inhibitor 
production was detected by using our NMR assay, thus implying a divergent evolution of the 
sensory system of both species to adapt to their respective host organisms. P. luminescens 
obviously requires a different molecular trigger present in insects to start its pathogenic phase. 
Screening of diverse growth media with our NMR-based methodology revealed that an 
osmotic shock is necessary to mimic the environmental changes upon intrusion into the insect 
body and in turn to initiate inhibitor secretion (Supplementary Information). Proteolytic 
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processing of the substrate peptide was completely precluded under these conditions, 
indicating the presence of at least one highly potent CP inhibitor.   
Isolation and structure elucidation of the inhibitors. To identify the CP inhibiting 
compounds from Photorhabdus, we have established an isolation procedure from liquid broth 
(see Online Methods). Intriguingly, from 3 L culture broth we received two CP inhibitors with 
a final yield of 10 mg each exhibiting molecular masses of 520 and 534 g·mol-1. Comparison 
of the LC-MS profile with a Photorhabdus culture exclusively grown at high salt condition 
revealed that the spectrum of secondary metabolites changed dramatically, thus reflecting a 
complete switch of life stages including the production of proteasome inhibitors 
(Supplementary information Fig. S1).  
Structure elucidation of the two compounds by 2D-NMR analysis resulted in the molecules 
glidobactin A (GlbA),  which had been known to be the strongest proteasome inhibitor 
identified so far  (23, 24), as well as a molecule that has been named cepafungin I (CepI) in 
literature (25) (Fig. 2A). Despite the high similarity of the isolated molecules, CepI has never 
been investigated with respect to its properties as a proteasome inhibitor. Both CepI and GlbA 
share a 12 membered macrolactam ring system that is linked to a fatty acid tail. As the only 
difference, this apolar chain is terminally branched and carries an additional methyl moiety in 
the case of CepI, whereas it is linear in GlbA.  
In vitro functional and structural characterization of GlbA and CepI. Investigating the 
inhibitory potential of both compounds, we performed IC50 measurements with yeast CP 
using the established NMR assay for the ChTL activities. Remarkably, the IC50-value for CepI 
(4 nM) was five times lower compared to GlbA (19 nM, Fig.2C). Evaluation of the 
stoichiometry between CepI and CP reveals that 100% inhibition is already observed at a ratio 
of 2:1, thus reaching the detection limit of the assay with regard to the two-fold symmetry of 
the proteasomal subunits. These results could be verified by established fluorescence based 
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assays, as the isolated compounds were uncolored and therefore did not cause quenching 
effects compared to the crude culture broth. Moreover, the high consistency between the data 
gained from both recording techniques confirms the equivalence of the NMR approach, using 
a natural and active-site specific proteasome substrate, in contrast to common assay types. In 
addition, measurements were expanded on evaluation of the TL and CL sites. The TL activity 
was inhibited to 24 nM for CepI and 193 nM for GlbA, respectively, thus exhibiting the same 
tendency as observed for the β5 subunit (Fig. S2). The proteasomal CL activity was not 
affected by either compound up to concentrations as high as 100 µM. These results were 
surprising since only a minor change such as a methyl group at the distal end from the active 
proteasomal Thr-1Oγ residue has such an impact on the binding affinity. 
Therefore, we performed crystal structure analysis of CepI and GlbA in complex with the 
yeast CP at 2.6 Å (Rfree=24.3%) and 3.0 Å (Rfree=22.7%) resolution for characterizing both 
inhibitors at the molecular level (Supplementary Information). Electron densities display 
covalent and irreversible binding of Thr-1Oγ to the macrolactam ring via ether bond 
formation, which was confirmed by a gel shift assay (Fig. 2D-E). Intriguingly, the aliphatic 
fatty acid chains of GlbA and CepI point towards a hydrophobic patch formed by subunit β6 
adjacent to the catalytically active β5 subunit. However, in contrast to the linear aliphatic 
chain of GlbA, the branched isopropyl side chain of CepI is further stabilized in a lipophilic 
pocket by strong van-der-Waals interactions (Fig. 2E-G). In conclusion, structural evaluation 
of SylA, GlbA and CepI suggests a directed evolution: starting from a charged and highly 
polar moiety adjacent to the macrolactam scaffold with impaired binding affinity, continuing 
with enhanced decoration as well as exploitation of the distant hydrophobic pocket in GlbA 
by an aliphatic linker and eventually yielding an optimized solution with maximum inhibition 
values for CepI. Analysis of the other active proteasomal subunits reveals that the β2 active 
site is occupied, whereas β1 was found empty, hereby confirming the in vitro results. 
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Equivalently to β5, the enhanced inhibitory strength of CepI versus GlbA against the TL 
activity can be explained by apolar interactions with a distal lipophilic patch via its branched 
fatty acid tail. 
Cell culture experiments. In order to investigate cytotoxic effects on HeLa cancer cells upon 
treatment with GlbA/CepI, we determined the time-dependent viability at a final compound 
concentration of 1 µM (Fig. 3A). Both compounds, GlbA and CepI, exhibit significantly 
increased cytotoxicity versus the standard proteasome inhibitor MG132, an artificial and cell 
penetrating aldehyde peptide (27). This finding is also in agreement with their superior 
binding strength over MG132, which features an IC50 value of 270 nM against the ChTL 
activity in vitro. Although it has been shown that inhibition of β5 alone is sufficient for 
cytotoxicity of a compound, it is considerably increased if also a second subunit is affected 
(28). This furthermore explains the enhanced effects of the syrbactin compounds, which bind 
both to the β5 and the β2 subunits. Comparison between CepI and GlbA reveals that cancer 
cells treated with CepI displayed increased lethality than in the case of GlbA, again reflecting 
the results received by the in vitro experiments.  
Assessing intracellular proteasome inhibition upon treatment with both natural compounds, 
we analyzed degradation of the natural proteasome substrate IκB. In most human cells, the 
nuclear NF-κB transcription factor is inactively sequestered in the cytosol by the inhibitory 
IκB protein, whose ubiquitin mediated degradation is initiated by the inflammatory cytokine 
IL-1 (29). By incubation with GlbA or CepI before addition of IL-1, however, the digestion of 
IκB is prevented, hence demonstrating the cell penetration and intracellular proteasome 
inhibition by the natural compounds (Fig. 3B). 
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Discussion 
The results gained by our experiments are promising and make CepI a candidate for further 
drug development. Being the most powerful proteasome inhibitor described to date, its 
secretion is strictly controlled in Photorhabdus (Supplementary information). The bacterium, 
which lives in the gut of the nematode Heterorhabditis, presumably suspends production of 
GlbA and CepI until it is released into the hemocoel of an insect larva, whereupon they kill 
their mutual prey in a concerted action to reproduce new bacteria and nematodes (30). Hence, 
GlbA and CepI are proteasome inhibitors to which a biological function could be assigned. 
Despite the rigid environmental regulation, the discovery of the two natural compounds from 
Photorhabdus was feasible due to the novel approach established in this work. The 
determination of the appropriate stimuli for pathogenic organisms to enter the virulent life-
stages, when most secondary metabolites are produced, is of crucial importance, as the 
majority of all genes involved in production of natural compounds are usually found silent 
under common growth conditions. As many other organisms, like the human pathogen 
Burkholderia pseudomallei, carry gene clusters for putative proteasome inhibitors, the 
application of the developed methodology for screening of such triggers will identify 
promising new natural products, which may lead to the development of new drugs for 
treatment of various diseases. Eventually, we anticipate that a transfer of the established 
screening procedure to other targets of pharmaceutical interest will facilitate the identification 
of natural inhibitory compounds for these enzymes. 
Materials and Methods 
NMR proteasome assay. Purification of the 20S proteasome from S. cerevisiae was 
performed as described previously (3). The assay mixture containing 10 µg/ml yeast CP, 100 
mM Tris (pH 8.0), 0.01% SDS and 300 µl sterile filtrated culture broth was incubated for 10 
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minutes at RT. Labeled peptide was added to a final concentration of 2 mM and incubated for 
6 hours. The assay was quenched by ultrafiltration, completed with D2O and recorded in a 500 
MHz spectrometer (Bruker Topspin 13C-Cryo NMR). IC50 measurements were carried out 
accordingly with the purified compounds dissolved in DMSO. Remaining activity was 
calculated by scaling the ratio of the product to the educt peak and compared with a blank 
sample. 
Secretion and Purification of GlbA/CepI. A preculture of P. luminescens ssp. laumondii 
(DSM No 15139) was grown at high osmolarity (0.2% Tryptone, 0.5% Yeast Extract, 1% 
NaCl) for three days at 28 °C, which was then used to inoculate medium without NaCl in a 
1/100 ratio. During further incubation for three days, a hydrophobic resin (XAD-16) was 
added to the culture broth, which was afterwards extracted with methanol. The extract was 
subjected to a silica column, which was washed with cyclohexane and eluted with ethyl 
acetate. Fractions containing inhibitors were identified by the proteasome assay and applied to 
RP-C18 HPLC chromatography. GlbA and CepI eluted at approximately 55% acetonitrile in a 
10-70% gradient over 1 h on a 250/10 mm column. 
Cell culture assay. Viability measurements with HeLa cells were performed at a final 
inhibitor concentration of 1 µM at 6, 10, 24 and 48 hours by Alamar Blue assays as described 
previously (31); MG132 was purchased from Bachem. For Western blot analysis of IκB 
accumulation, HeLa cells were incubated with 40 µM inhibitors for 6 hours and then 
stimulated by addition of IL-1 at a concentration of 30 ng/ml for 20 minutes before 
harvesting. After cell lysis, 10 µg protein was applied to 15% SDS-PAGE. Western blot 
analysis of IκB was standardized by comparison to the GADPH housekeeping protein. 
 
 
 
  
11 
 
 
Acknowledgements 
We thank Richard Feicht for yeast proteasome purification as well as Nerea Gallastegui, 
Haissi Cui and Achim Krüger for assistance in cell culture assays. Katja Bäuml is 
acknowledged for help with peptide synthesis.  We are grateful to the staff of the Beamlines 
X06SA and X06DA at the Paul Scherrer Institute, SLS, Villingen, Switzerland for their 
support during data collection. M. K. was funded by an ERC starting grant (grant No. 
258413). 
 
Author contributions 
M.G. designed experiments. C.B. designed and synthesized the peptide substrate; R.D. 
provided P.syringae strains and conditioned media. Isolation of natural products and structure 
elucidation was performed by M.S. and P.B. Activity tests, crystallographic experiments and 
cell culture assays were conducted by M.S.; M.G. and M.S. collected and analyzed 
crystallographic data. M.K. contributed to the interpretation of the received results. M.G. and 
M.S. wrote the manuscript. 
 
Author information 
The authors declare no conflict of interest. 
Data deposition: The atomic coordinates and structure factors have been deposited in the 
Protein Data Bank, www.pdb.org [PDB ID codes 4FZC (CP:CepI) and 4FZG (CP:GlbA)]. 
Correspondence and requests for materials should be addressed to M.G. 
(michael.groll@ch.tum.de). 
 
 
 
  
12 
 
References 
1. Hershko A, Ciechanover A (1998) The ubiquitin system. Annu Rev Biochem 67:425-
479. 
2. Gallastegui N, Groll M (2010) The 26S proteasome: assembly and function of a 
destructive machine. Trends Biochem Sci 35(11):634-642. 
3. Groll M, et al. (1997) Structure of 20S proteasome from yeast at 2.4 A resolution. 
Nature 386(6624):463-471. 
4. Huber EM, et al. (2012) Immuno- and constitutive proteasome crystal structures 
reveal differences in substrate and inhibitor specificity. Cell 148(4):727-738. 
5. Unno M, et al. (2002) Structure determination of the constitutive 20S proteasome 
from bovine liver at 2.75 A resolution. J Biochem 131(2):171-173. 
6. Orlowski M (1990) The multicatalytic proteinase complex, a major extralysosomal 
proteolytic system. Biochemistry 29(45):10289-10297. 
7. Huber EM, Groll M (2012) Inhibitors for the immuno- and constitutive proteasome: 
current and future trends in drug development. Angew Chem Int Ed  51(35):8708-
8720. 
8. Richardson PG, Hideshima T, Anderson KC (2003) Bortezomib (PS-341): a novel, 
first-in-class proteasome inhibitor for the treatment of multiple myeloma and other 
cancers. Cancer Control 10(5):361-369. 
9. Arastu-Kapur S, et al. (2011) Nonproteasomal targets of the proteasome inhibitors 
bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res 
17(9):2734-2743. 
10. Gräwert M, Groll M (2012) Exploiting nature's rich source of proteasome inhibitors as 
starting points in drug development. Chem Commun  48(10):1364-1378. 
11. Khan M, Stewart AK (2011) Carfilzomib: a novel second-generation proteasome 
inhibitor. Future Oncol 7(5):607-612. 
12. Meng L, et al. (1999) Epoxomicin, a potent and selective proteasome inhibitor, 
exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci U S A 96(18):10403-
10408. 
13. Groll M, Kim K, Kairies N, Huber R, Crews C (2010) Crystal structure of 
epoxomicin:20S proteasome reveals molecular basis for selectivity of α'β'-
epoxyketone proteasome inhibitors. J Am Chem Soc, pp 1237-1238. 
14. Dick TP, et al. (1998) Contribution of proteasomal beta-subunits to the cleavage of 
peptide substrates analyzed with yeast mutants. J Biol Chem 273(40):25637-25646. 
15. Adams J, et al. (1998) Potent and selective inhibitors of the proteasome: dipeptidyl 
boronic acids. Bioorg Med Chem Lett 8(4):333-338. 
16. Wäspi U, Blanc D, Winkler T, Rüedi P, Dudler R (1998) Syringolin, a Novel Peptide 
Elicitor from Pseudomonas syringae pv. syringae that Induces Resistance to 
Pyricularia oryzae in Rice. Molecular Plant-Microbe Interactions, pp 727-733. 
17. Schellenberg B, Bigler L, Dudler R (2007) Identification of genes involved in the 
biosynthesis of the cytotoxic compound glidobactin from a soil bacterium. Environ 
Microbiol 9(7):1640-1650. 
18. Krahn D, Ottmann C, Kaiser M (2011) The chemistry and biology of syringolins, 
glidobactins and cepafungins (syrbactins). Nat Prod Rep 28(11):1854-1867. 
19. Wiersinga WJ, van der Poll T, White NJ, Day NP, Peacock SJ (2006) Melioidosis: 
insights into the pathogenicity of Burkholderia pseudomallei. Nat Rev Microbiol 
4(4):272-282. 
  
13 
 
20. Frackman S, Anhalt M, Nealson KH (1990) Cloning, organization, and expression of 
the bioluminescence genes of Xenorhabdus luminescens. J Bacteriol 172(10):5767-
5773. 
21. Brachmann AO, et al. (2012) Triggering the production of the cryptic blue pigment 
indigoidine from Photorhabdus luminescens. J Biotechnol 157(1):96-99. 
22. Waspi U, Blanc D, Winkler T, Ruedi P, Dudler R (1998) Syringolin, a novel peptide 
elicitor from Pseudomonas syringae pv. syringae that induces resistance to Pyricularia 
oryzae in rice. Molecular Plant-Microbe Interactions 11(8):727-733. 
23. Groll M, et al. (2008) A plant pathogen virulence factor inhibits the eukaryotic 
proteasome by a novel mechanism. Nature 452(7188):755-758. 
24. Oka M, et al. (1988) Glidobactins A, B and C, new antitumor antibiotics. I. 
Production, isolation, chemical properties and biological activity. J Antibiot 
41(10):1331-1337. 
25. Shoji J, et al. (1990) Isolation of cepafungins I, II and III from Pseudomonas species. 
J Antibiot 43(7):783-787. 
26. Loewe J, et al. (1995) Crystal Structure of the 20S Proteasome from the Archaeon T. 
acidophilum at 3.4 A Resolution. Science 268(5210):533-539. 
27. Bush KT, Goldberg AL, Nigam SK (1997) Proteasome inhibition leads to a heat-
shock response, induction of endoplasmic reticulum chaperones, and thermotolerance. 
J Biol Chem 272(14):9086-9092. 
28. Screen M, et al. (2010) Nature of pharmacophore influences active site specificity of 
proteasome inhibitors. J Biol Chem 285(51):40125-40134. 
29. Ortis F, et al. (2012) Differential usage of NF-κB activating signals by IL-1β and 
TNF-α in pancreatic beta cells. FEBS Lett 586(7):984-989. 
30. Waterfield NR, Ciche T, Clarke D (2009) Photorhabdus and a host of hosts. Annu Rev 
Microbiol 63:557-574. 
31. Macherla V, et al. (2005) Structure-activity relationship studies of salinosporamide A 
(NPI-0052), a novel marine derived proteasome inhibitor. J Med Chem 48(11):3684-
3687. 
 
 
Figure Legends 
Fig. 1. NMR peptide assay. (A) Primary sequence of the substrate with the scissile peptide 
bond and the 13C label. (B) NMR spectrum of substrate digestions with the uncleaved educt 
and the carboxylic acid product at 173 and 177 ppm, respectively (upper panel). Product peak 
formation is suppressed upon addition of a CP inhibiting culture broth (lower panel). 
Fig. 2. In vitro functional and structural characterization of GlbA and CepI. (A) NMR 
deduced structures of GlbA/CepI with the proteasome binding sites S1 and S3 as well as the 
hydrophobic patch SL. (B) SylA, featuring a hydrophilic carboxylic acid tail.  (C) IC50 curves 
for the ChTL activity measured for GlbA (green) and CepI (blue) with 13C labeled peptide 
  
14 
 
substrate; black curves depict equivalent measurements with the fluorogenic Suc-Leu-Leu-
Val-Tyr-AMC substrate (error bars are too small to be visible) . (D) Western blot on a β5-
(His)6 yeast CP mutant +/- treatment with CepI. The gel shift indicates an increased molecular 
mass by covalent and irreversible binding. (E) Structural superposition of GlbA and CepI 
bound to yeast CP; the differing methyl moiety is indicated by a red arrow. (F) Surface 
representation of CepI in the β5 substrate binding channel. Colors indicate positive and 
negative electrostatic potentials contoured from -30 kT/e (bright red) to +30 kT/e (bright blue) 
(G) Stereoview of the 2Fo - Fc omit electron density map (grey mesh, 1σ) for the β5 active site. 
Hydrogen bonds are indicated by dashed lines, whereas the arrow pronounces the accurate 
fitting of the P1 methyl side chain of the inhitibor. The lipophilic pocket of the SL site is 
formed by Tyr-5, Pro94, Tyr96 and Pro115 from β6 (amino acid numbering according to 
Löwe et al. (26). 
Fig. 3. Cell culture assays. (A) Cytotoxicity is measured by performing the Alamar Blue 
assay with HeLa cells after 6, 10, 24 and 48 h for MG132 (black), GlbA (green) and CepI 
(blue) at 1 µM concentration. (B) Western blot on IκB +/- IL-1 induction in HeLa cells, which 
were treated for 6 hours with 50 µM of MG132, GlbA, CepI or DMSO. Proteasomal IκB 
degradation is initiated by IL-1 signaling, whereas it is prevented after addition of the cell 
penetrating CP inhibitors. The GADPH housekeeping protein was co-stained for 
quantification. 
Online Methods 
Peptide synthesis. The 13C-labeled CP substrate peptide was synthesized at a 0.2 mmol scale 
on a custom-modified Applied Biosystems 433A peptide synthesizer using S-DVB (stryrene-
divinylbenzene) resin carrying an -OCH2-PAM (Applied Biosystems, Foster City, CA) and a 
thioester-generating linker following an in-situ neutralization protocol for machine-assisted 
Boc (tert.-butoxycarbonyl) chemistry (32, 33). Side chain protecting groups were: Arg(Tos), 
Asn(Xan), Glu(OcHx), Ser(Bzl) and Tyr(2BrZ). Boc-Phe(Cα-13C) was obtained from euriso-
top. The peptide was released from resin by treatment with liquid HF for 1 hour at 0 °C in the 
presence of 5% (v/v) p-cresol. 10 ml of liquid HF were used for 1 g of peptide-resin. 
Purification of the crude peptide was achieved using a semipreparative RP-HPLC C4-column 
(Grace, Lokeren, Belgium) and a gradient of 40 to 65% buffer B (acetonitrile + 0.08% TFA) 
in buffer A (water + 0.1% TFA) over 60 minutes. Product containing fractions were identified 
by ESI-MS (electrospray ionization mass spectrometry) and pooled accordingly. 24% of 
purified peptide was obtained from crude material and dissolved in DMSO for application in 
digestion assays. 
 
Secretion and Purification of GlbA/CepI. Bacteria were grown in TYEA medium (0.2% 
Bacto-Tryptone, 0.5% Yeast Extract, 1% NaCl per litre) for 3 days at 28 °C. This culture was 
used to inoculate TYEB medium (TYEA without NaCl) at a ratio of 1/100. Solid adsorber 
resin (XAD-16) was added to the culture broth, which was in turn incubated for three days. 
The resin was filtrated and extracted with methanol. After concentrating the sample by 
evaporation, it was applied to a silica column (Silica Gel 60 by Merck). The column was 
washed with cyclohexane and eluted with ethylacetate. All fractions were tested by the NMR 
proteasome assay and positive fractions were applied to preparative HPLC chromatography 
(RP-C18, 150 mm, 1 cm id, 3.5 µm) with a gradient of 10-70% acetonitrile within 60 minutes. 
Fractions were again tested by the NMR assay; GlbA and CepI eluted at approximately 55% 
acetonitrile. Mass spectrometrical analysis was perfomed by ESI-MS (Thermo-Fisher-
Scientific Orbitrap). NMR measurements for structure elucidation were carried out in D6-
DMSO at 500 MHz with respective compound concentrations of 25 mM. 
IC50 measurements by fluorogenic substrates. In vitro proteasome inhibition assays were 
performed in 96-well microtiter plates with 10 µg/ml yeast CP in 100 mM Tris (pH 8.0) 
supplemented with 0.01% SDS. Inhibitors were added in DMSO at various concentrations 
with three repetitions each. After a reaction time of 30 minutes, the fluorogenic substrates 
Suc-Leu-Leu-Val-Tyr-AMC, Z-Ala-Arg-Arg-AMC or Z-Leu-Leu-Glu-AMC were added for 
analysis of ChTL, TL the CL activities, respectively. The assay mixture was incubated for 
further 60 minutes; fluorescence and excitation were monitored with a Varian Cary Eclipse 
Photofluorometer at 460 nm and 360 nm, respectively,  
Gel shift assay. A tagged β5-(His)6 yeast proteasome mutant was incubated at a concentration 
of 1 mg/ml with inhibitor or DMSO in 100 mM Tris pH 8.0 for one hour and applied to a 
12% SDS-PAGE. The β5-(His)6 subunit was stained by Western blot analysis. Covalent and 
irreversible modification of the subunit is accompanied by a gel shift, whereas non-covalent 
or reversible inhibitors detach during electrophoresis. 
Cocrystallisation and structure elucidation. Crystals of the yeast CP were grown in 
hanging drops at 24 °C as described (34). The protein concentration used for crystallisation 
was 40 mg/ml in Tris-HCl (10 mM, pH 7.5) and EDTA (1 mM). The drops contained 3 µl of 
protein and 2 µl of the reservoir solution (30 mM magnesium acetate, 100 mM morpholino-
ethane-sulphonic acid (pH 7.2) and 10% 2-methyl-2,4-pentanediol). Crystals were incubated 
at 2 mM inhibitor concentration for 24 hours, followed by soaking in a cryoprotecting buffer 
(30% MPD, 20 mM magnesium acetate, 100 mM morpholino-ethane-sulfonic acid pH 6.9) 
and super-cooled in a stream of liquid nitrogen gas at 100 K (Oxford Cryo Systems). 
Data of the CP:CepI and the CP:GlbA complexes were collected to 2.8 and 3.0 Å, 
respectively, using synchrotron radiation (λ = 1.0 Å) at the X06SA-beamline 
(SLS/Villingen/Switzerland). The space group belongs to P21 with cell dimensions of a=134 
Å, b=301 Å, c=144 Å and β =112° (see Supplementary Table S3). X-ray intensities were 
evaluated by using XDS (35) and data reduction was performed with XSCALE (35). The 
anisotropy of diffraction was corrected by an overall anisotropic temperature factor by 
comparing observed and calculated structure amplitudes using the program CNS (36). 
Electron density was improved by averaging and back transforming the reflections 10 times 
over the twofold non-crystallographic symmetry axis using the program package MAIN (37). 
Conventional crystallographic rigid body, positional and temperature factor refinements were 
carried out with CNS using the yeast 20S CP structure as starting model (PDB accession code 
1RYP) (3). Model building was performed with the program MAIN (37). Apart from the 
bound inhibitor molecules, structural changes were only noted in the specificity pockets. 
Temperature factor refinement indicates full occupancies of all inhibitor binding sites.  
32. Camarero JA, Muir TW (1999) Chemical Ligation of Polypeptides.  Current Protocols 
in Protein Science, pp 18.14.11-18.14.21. 
33. Schnölzer M, Alewood P, Jones A, Alewood D, Kent SB (1992) In situ neutralization 
in Boc-chemistry solid phase peptide synthesis. Rapid, high yield assembly of difficult 
sequences. Int J Pept Protein Res 40 (3-4):180-193. 
34. Groll M & Huber R (2005) Purification, crystallization, and X-ray analysis of the 
yeast 20S proteasome. Methods Enzymol 398:329-336. 
35. Kabsch W (2010) XDS. Acta Crystallogr D Biol Crystallogr 66 (Pt 2):125-132. 
36. Brünger AT, et al. (1998) Crystallography & NMR system: A new software suite for 
macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 54 (Pt 
5):905-921. 
37. Turk D (1992) Improvement of a programm for molecular graphics and manipulation 
of electron densities and its application for protein structure determination. Thesis 
Technische Universitaet Muenchen.    
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Analysis of peptide cleavage pattern and specificity. The peptide cleavage site was 
determined by LC-MS analysis of the digestion products in an in vitro assay containing 10 
µg/ml yeast CP, 100 mM Tris (pH 8.0), 0.01% SDS, 10% DMSO and 2 mM peptide, which 
was incubated for 6 hours at 37 °C. Confirming the specificity of the probe molecule towards 
the β5 subunit, hydrolysis was prevented in the same assay after addition of the synthetic 
boronic acid inhibitor MG262 (Enzo Life Sciences), which exhibits inhibition merely of the 
ChTL activity. 
 
Induction of biosynthesis of GlbA and CepI in P. luminescens. Initially, an NMR screen of 
Photorhabdus cultures was carried out to detect suitable growth conditions for inhibitor 
secretion. However, application of standard media and variation of their respective 
composition, as well as complementation with various additives, failed to initiate the 
pathogenic phase in Photorhabdus. Furthermore, mimicking previously described conditions 
for producing SylA and GlbA from P. syringae and Burkholderiales strain K481-B101 did 
not yield any positive result. We therefore performed inoculation experiments by transmission 
of precultured Photorhabdus bacteria to differently conditioned media to analyze the effects 
of environmental shifts. An abrupt change of osmolarity, going from 170 mM to 0 mM NaCl, 
resulted in complete inhibition of the proteasome in our NMR assay, thus identifying the 
conditions to trigger the virulent phase. In agreement to previous findings (1, 2), we could 
demonstrate that there is no consensus between the different molecular stimuli among the 
organisms producing SylA related compounds. To further confirm the quality of our NMR 
based assay we performed LC-MS runs of Photorhabdus cultures with or without submission 
to an osmotic shock and could show that under common growth conditions none of the 
inhibitors is detectable (Figure S1). In conclusion, our data indicate that secretion of GlbA 
and CepI is limited to a well-defined environmental shift, reflecting the distinct life-stages of 
Photorhabdus. 
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Table S1. Screening of different media and additives.  
Standard media: LB, 2xTY, CY, SRM, TYEA, PDB, DSMZ media 1, 54, 220 
Changed parameters in these media:  Sugar, Casitone, Peptone, yeast extract and salt 
ingredients 
Additives:      Fructose, maltose, arbutin, sucrose and lactose 
      L-proline, L-arginine 
Iron(III)chloride, iron(II)chloride, soluble and 
insoluble magnesium and calciumsalts 
Other parameters:   Temperature (18 to 34 °C in steps of 2 °C), 
rotation speed, incubation time (one to ten days), 
inocculation density 
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Figure S1: Comparison between GlbA and CepI secretion in standard medium and after 
osmotic shock. LC-MS runs of saturated Photorhabdus cultures grown in 2xTY (A)  
or TYEA/TYEB induction media (B). In agreement to our NMR results, both samples  
display significant differences in the elution interval between 20 and 40 minutes. The 
proteasome inhibitors GlbA (21.38 minutes, blue bar) and CepI (22.92 minutes, green bar) 
were only detected in the culture treated with TYEB (B).   
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Purification of GlbA and CepI from P. luminescens secretions. Secretions and extracts of 
microorganisms are often colored, making UV-Vis based assay techniques prone to color 
quenching artifacts. Photorhabdus produces a whole range of colored substances (Figure S2). 
 
 
 
 
 
 
Figure S2: Colored culture broth of P. luminescens. The culture broth has a dark shade of 
red (left), rendering UV-Vis based techniques impossible. Chromatographic separation on a 
silica column (right) reveals that a whole array of colored substances is produced by 
Photorhabdus. 
 
IC50 measurements of the CL and TL activities. Just as in the case of the ChTL activity, 
inhibition of the β2 subunit is enhanced for CepI (Fig. S3), thus reflecting increased 
hydrophobic interactions between its aliphatic fatty acid chain and the adjacent β3 subunit. In 
contrast, neither of the compounds binds to β1, which is again in agreement with the in vitro 
assay results. 
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Figure S3: Inhibition of the TL activity. The IC50 value of CepI (blue curve) is six times 
decreased compared to GlbA (green). 
 
NMR structure elucidation of GlbA and CepI. NMR peak assignments are listed in table 
S2 and refer to the atom numbering in figure S4. All spectra were recorded at 500 MHz in D6-
DMSO. 
Figure S4: Molecular Structure of CepI with atom labelling 
 
 
Table S2. NMR Spectroscopic data (D6-DMSO) for CepI (a) and GlbA (b) 
 
 δH, mult. (J [Hz]) δC  Type   COSY  HMBC 
                                               
1a, 2a 0.84, d, (3.25)  23.03  CH3  3a  1a, 2a, 3a, 4a 
3a 1.50, m  27.82  CH  1a, 2a, 4a 1a, 2a, 4,a 5a 
4a 1.15, m   38.86  CH2   3a, 5a  1a, 2a, 3a, 5a, 6a 
1b 0.86, t (7.0)  14.46  CH3  3  3b, 4b 
3b 1.26, m  31.68  CH2  1b  1b 
4b 1.26, m  26.21  CH2   
5 1.26, m  27.08  CH2  4a 
6 1.26, m  29.21  CH2 
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7 1.39, m  28.81  CH2  8  5, 6, 8 
8 2.13, m  32.76  CH2  7, 9  7, 9, 10 
9 6.11, m  142.68  CH  8, 10  7, 8, 10, 11 
10 6.19, m  129.49  CH  9, 11  8, 9, 11  
11 7.00, dd (15.0, 10.0) 140.24  CH  10, 12  9, 10, 12, 13 
12 6.13, m  123.49  CH  11  11, 13 
13 -   165.88  C(O)    11, 12 
14 7.91, d (9.0)  -  NH  15  13, 15 
15 4.29, m  58.49  CH  14, 16  16, 17, 18 
16 3.97, m  67.18  CH  15, 17   
17 1.0, d (10)  20.46  CH3  16  15, 16 
18 -   169.86  C(O)    15, 19 
19 7.76, d (7.0)  -  NH  20  18, 20, 21 
20 4.34, m  51.66  CH  19, 32   
21 -   171.44  C(O)    19 
22 8.69   -  NH  23 
23 4.37, m  45.21  CH  22, 24, 25  
24 1.22, m  19.05  CH3  23  23 
25 6.41, d (15.0)  143.56  CH  26   
26 6.19, m  140.23  CH  25  26 
27 -   168.09  C(O)    25, 29 
28 7.44, t (5.5)  -  NH  29  26, 29, 30  
29 3.02, m  40.40  CH2  28, 30  27, 28, 30 
30 1.45, m  40.07  CH2  29, 31  29 
31 3.58, m  67.57  CH  30, 32  30 
32 1.85, m  42.93  CH2  31, 32, 20  
 1.58, d (11.5) 
 
 
Crystallographic data. Despite the existing structural information of the CP:GlbA complex 
(PDB code 3BDM), we performed crystal structure analysis also with the isolated natural 
compound from Photorhabdus for direct comparison, as the crystallization conditions were 
slightly modified. 
 
Table S3. Data collection and refinement statistics.  
 
    CP:CepI a    CP:GlbA a 
 
Crystal parameters      
Space group   P21    P21    
Cell constants (Å) / °  a=135,7   134.8 
(dataset was collected from  b=301,0   300.4 
1 crystal / 1 CP per AU) c=144,8   144.5 
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    β=112,9   112.7 
Data collection 
Beamline    X06SA, SLS 
Wavelength (Å)  1.0 
Resolution range (Å) b  25-2.8    15-3.0 
No. observations  837332    724190 
No. unique reflections c  256455    209581 
Completeness (%) b  97,8 (99,0)   99.3 (99.7) 
Rmerge b, d   7,7 (61,4)   6.7 (47.2) 
I/σ (I) b    13,0 (2,4)   15.2(3.2) 
 
Refinement 
(CNS) 
Resoltution range (Å)  15-2,8    15-3.0 
No. refl. working set  242408    197883 
No. refl. test set  12718    10363 
No. non hydrogen  49548    49548 
No. of ligand atoms  140    136 
Water    1320    1290 
Rwork/Rfree (%) e    21.3 / 24.3   19.8 / 22.7 
rmsd bond (Å) / (°) f  0.007 / 1.32    0.007 / 1.32 
Ramachandran Plot (%) g 95.0 / 4.7 / 0.3   94.7 / 4.8 / 0.5 
 
a
 Dataset has been collected on a single crystal 
b
 The values in parentheses of resolution range, completeness, Rmerge and I/σ (I) correspond to 
 the last resolution shell 
c
 Friedel pairs were treated as identical reflections 
d
 Rmerge(I) = ΣhklΣj |[I(hkl)j - I(hkl)] |/Σhkl Ihkl , where I(hkl)j is the measurement of the intensity of 
reflection hkl and <I(hkl)> is the average intensity 
e
 R = Σhkl | |Fobs| - |Fcalc| |/Σhkl |Fobs|, where Rfree  is calculated without a sigma cut off for a 
 randomly chosen 5% of reflections, which were not used for structure refinement, and Rwork 
 is calculated for the remaining reflections 
f
 Deviations from ideal bond lengths/angles 
g
 Number of residues in favoured region / allowed region / outlier region 
 
 
1. Waspi U, Blanc D, Winkler T, Ruedi P, & Dudler R (1998) Syringolin, a novel peptide elicitor 
from Pseudomonas syringae pv. syringae that induces resistance to Pyricularia oryzae in rice. 
Molecular Plant-Microbe Interactions 11(8):727-733. 
2. Oka M, et al. (1988) Glidobactins A, B and C, new antitumor antibiotics. I. Production, 
isolation, chemical properties and biological activity. J Antibiot (Tokyo) 41(10):1331-1337. 
 
 
